Construction and application of a risk prediction model for moderate to severe cancer-related fatigue in patients undergoing chemotherapy of prostate cancer
10.3760/cma.j.cn211501-20210726-02115
- VernacularTitle:前列腺癌化疗患者中重度癌因性疲乏风险预测模型的构建及验证
- Author:
Jing YUAN
1
;
Yamei CHEN
;
Yongzhen LIU
;
Xulin HE
;
Linlin SHI
;
Yun WANG
Author Information
1. 上海市第十人民医院泌尿外科，上海 200072
- Keywords:
Nomograms;
Prostatic neoplasms;
Chemotherapy;
Cancer-related fatigue;
Risk prediction model
- From:
Chinese Journal of Practical Nursing
2022;38(28):2170-2177
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the risk factors of moderate to severe cancer-related fatigue (CRF) in patients undergoing chemotherapy of prostate cancer, and to construct a nomogram model to predict the occurrence of CRF.Methods:Using the case data questionnaire, Brief Fatigue Inventory, Social Support Rating Scale and International Prostate Symptom Scores, 724 patients of prostate cancer treated by chemotherapy in Shanghai Tenth People′s Hospital from August 2016 to June 2021 were selected and were treated with 1∶1 ratio, and the indexes of the moderate and severe CRF group (216 cases) and the non-moderate and severe CRF group (216 cases) were compared. According to the ratio of 7∶3, the envelope method was used to divide into training set and validation set. The independent risk factors of moderate and severe CRF were explored by univariate analysis and multivariate Logistic regression analysis, and the risk prediction model was established and the nomogram model was constructed. The C-index and area under ROC curve were used to verify the prediction effect of the model.Results:Multivariate Logistic regression analysis showed that BMI ranged from 24.0 to 27.9 kg/m 2 ( OR=1.733), BMI≥28.0 kg/m 2 ( OR=3.126), neutropenia occurred during chemotherapy ( OR=1.747), chemotherapy course >6 months ( OR=1.893), moderate social support level ( OR=1.244), low social support level ( OR=2.434), mild urinary tract symptoms ( OR=1.264), moderate urinary tract symptoms ( OR=3.371) and severe urinary tract symptoms ( OR=5.297) were independent risk factors for moderate and severe CRF. The nomogram model constructed according to the above risk factors was internally verified by the training set and the validation set, and its C-index was 0.854 and 0.741 respectively. The area under ROC curve training set was 0.823, and the validation set was 0.733. Conclusions:The nomogram model can effectively predict the occurrence of moderate to severe CRF in patients with prostate cancer undergoing chemotherapy.
